A Phase II Study of Docetaxel and Vinorelbine in Advanced Non-Small Cell Lung Carcinoma
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells.
Colony-stimulating factors such as filgrastim may increase the number of immune cells found
in bone marrow or peripheral blood and may help a person`s immune system recover from the
side effects of chemotherapy.
Phase II trial to study the effectiveness of combination chemotherapy plus
filgrastim in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Study Status: Active, not recruiting
Drug: vinorelbine tartrate
Information provided by:
National Cancer Institute (NCI)
Study Type: Interventional
Study Design: Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
Barbara Allen, DVM, MBA, PharmD., Study Chair